Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.82+3.94%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GLUE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -40.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GLUE — litigation filed
Dated 2026-10-01
Other Events On October 1, 2026, the Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of NLRP3/IL-1-driven inflammatory diseases. Summary of GFORCE-1 Results • GFORCE-1 enrolled 108 obese subjects with elevated CVD risk, randomized to MRT-8102 at 5 mg, 20 mg, or 40 mg once daily, or to placebo, for 4 weeks of dosing and 4 weeks of follow-up safety evaluation. • MRT-8102 achieved robust and sustained NEK7…
Why it matters: The study will test plaque changes and other disease markers in people with coronary artery disease. That is a step beyond short-term blood tests.
Supportive ifA company update or trial listing shows GFORCE-2 has started by June 30, 2027.
Worry ifGFORCE-2 has not started by June 30, 2027, or the company reports a delay tied to study support or safety testing.
Why it matters: More trials would test the drug in other immune diseases and could trigger more milestone payments to Monte Rosa.
Supportive ifNovartis starts at least one additional MRT-6160 Phase 2 study in an immune disease by December 31, 2026.
Worry ifNo additional MRT-6160 Phase 2 study starts by December 31, 2026, or Novartis reports a pause.
Why it matters: The new trial tests earlier signs of tumor response in a larger group. The first Phase 1/2 group had only six patients with AR mutations.
Watch forThe company reports results from the six-patient AR-mutation group. Most patients show tumor shrinkage or disease control.
Also watch forThe update shows little tumor shrinkage or disease control. Or, the company reports no data by December 31, 2026.
Why it matters: This gout study tests MRT-8102 in a second disease. It may also bring an early look at flare prevention.
Supportive ifA company update or trial listing shows GEMINI-1 has begun by March 31, 2027.
Worry ifGEMINI-1 has not begun by March 31, 2027, or the company delays its start date.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$217 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $617 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,152 loss on $10,000 · 61.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The study tests whether MRT-8102 can help prevent repeat gout flares after an acute flare is treated.
Watch forThe company reports first GEMINI-1 results in H2 2027. It shows fewer repeat flares with MRT-8102 than with the control group.
Also watch forInitial results show no reduction in repeat flares, or the data release slips past H2 2027.